Genelux Corp (GNLX) Financial Statements

GNLX Financial Data

EBITDA$-31.57M

Revenue (TTM)$0.00

Gross Profit (TTM)$0.00

Gross Margin—

Operating Margin—

ROE-278.46%

ROA-168.94%

Debt/Equity0.15

Current Ratio2.43

FCF$-26.37M

FCF Yield-24.31%

Piotroski F-Score—

Rev/Share (TTM)—

50-Day MA$2.64

200-Day MA$3.81

Shares Outstanding0.04B

GNLX Computed Insights

FCF$-26.37M

FCF Growth Rate—

EPS Growth (CAGR)—

WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

GNLX Financial Statements & Data

Genelux Corp (GNLX) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Genelux Corp's financial performance and position as a Healthcare company.

Trailing twelve-month (TTM) revenue is $0.00. Gross profit (TTM) is $0.00. EBITDA is $-31.57M. Earnings per share (EPS) is $-0.86. The P/E ratio is -3.37. Market capitalization is $108.45M.

Free cash flow (FCF) is $-26.37M. Weighted average cost of capital (WACC) is 10.00%.

Historical revenue data covers 6 years from FY20 to FY25. Net income history spans 6 years. Free cash flow and capital expenditure data spans 6 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Genelux Corp's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.